Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Return on Sales (2016 - 2025)

Northwest Biotherapeutics' Return on Sales history spans 16 years, with the latest figure at 45.51% for Q4 2025.

  • Quarterly results put Return on Sales at 45.51% for Q4 2025, down 7539.0% from a year ago — trailing twelve months through Dec 2025 was 15.88% (up 247.0% YoY), and the annual figure for FY2025 was 44.05%, up 1657.0%.
  • Return on Sales for Q4 2025 was 45.51% at Northwest Biotherapeutics, up from 84.7% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 120.9% in Q4 2024 to a low of 126.76% in Q2 2025.
  • The 5-year median for Return on Sales is 42.7% (2022), against an average of 40.73%.
  • The sharpest move saw Return on Sales soared 426574bps in 2021, then crashed -8922bps in 2025.
  • Year by year, Return on Sales stood at 57.43% in 2021, then soared by 43bps to 32.49% in 2022, then fell by -13bps to 36.82% in 2023, then surged by 428bps to 120.9% in 2024, then plummeted by -62bps to 45.51% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 45.51%, 84.7%, and 126.76% for Q4 2025, Q3 2025, and Q2 2025 respectively.